Stockscreener 앱 받기
9.23
4.89%
0.43
시간 외 거래:
9.27
0.04
+0.43%
전일 마감가:
$8.80
열려 있는:
$8.99
하루 거래량:
151.41K
Relative Volume:
0.89
시가총액:
$90.80M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-1.9764
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
+24.39%
1개월 성능:
+47.68%
6개월 성능:
-39.52%
1년 성능:
-80.19%
1일 변동 폭
$8.8954
$9.35
1주일 범위
$7.05
$9.35
52주 변동 폭
$4.64
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
CRBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.23 | 90.80M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Dermatomyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Acquires 11,400 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
BNP Paribas Financial Markets Makes New Investment in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
(CRBP) Proactive Strategies - news.stocktradersdaily.com
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $50.88 Average Target Price from Analysts - Defense World
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating - marketscreener.com
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating - marketscreener.com
Corbus Pharmaceuticals appoints new board chair - Investing.com Australia
Corbus Pharmaceuticals appoints new board chair By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Appoints New Chair of the Board - TipRanks
Corbus Pharmaceuticals (CRBP) Names New Chair to Board of Direct - GuruFocus
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewswire
Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming - Stock Titan
(CRBP) Investment Analysis - news.stocktradersdaily.com
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? - sharewise
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC - Defense World
Wells Fargo & Company MN Has $76,000 Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Tower Research Capital LLC TRC - Defense World
Oppenheimer Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $56.00 - Defense World
B. Riley Expects Reduced Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $40.00 - Defense World
Research Analysts Offer Predictions for CRBP Q2 Earnings - Defense World
HC Wainwright Issues Negative Forecast for CRBP Earnings - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Royal Bank of Canada Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? - Zacks Investment Research
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
CRBP: RBC Capital Lowers Price Target, Maintains Outperform Rati - GuruFocus
Oppenheimer Lowers Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Reduced by Analyst | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Adjusted by RBC Capital | CRBP Stock News - GuruFocus
CRBP: HC Wainwright & Co. Lowers Price Target for Corbus Pharmaceuticals | CRBP Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk - marketscreener.com
Corbus Pharmaceuticals (CRBP) Sees Price Target Reduction | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals: Q1 Earnings Snapshot - CTPost
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss - TipRanks
Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising E - GuruFocus
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising Early Trial Data | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corbus Pharmaceuticals Holdings Inc 주식 (CRBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
| Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
1.21%
1.51%
자본화:
|
볼륨(24시간):